Top 10 — Health Care — 1 Oct 2026
The ten as they stood on 1 Oct 2026. Scores, pillars and reasons are the ones recorded that day; nothing here is recomputed. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100.
The Top 10 score is a published weighted sum of percentile ranks, rebalanced on the first trading day of each month. A list is a published formula and its output, not a recommendation. Method version 4.
Get this list's changes every morning
One short email a day: who entered, who left, and the reason — with the score moves behind it.
Informational only — not financial advice. One email a day, unsubscribe in one click.
The ten
| # | Company | Why it was here | Sector | Score |
|---|---|---|---|---|
| 1 | AURINIA PHARMACEUTICALS INC (AUPH) | Profitability 94th (return on equity 49.4%, operating margin 37.1%).Profitability 94th (return on equity 49.4%, operating margin 37.1%) and growth 83rd (3-year revenue CAGR 28.3%, revenue growth year over year 19.8%); weakest is capital return (54th, consecutive years of dividend increases 0 years, net share count bought back over the year 5.1). |
Health Care | 79.6 |
| 2 | Incyte (INCY) | Financial health 86th (debt to equity 0, free cash flow margin 26.3%).Financial health 86th (debt to equity 0, free cash flow margin 26.3%) and profitability 85th (operating margin 29.5%, return on equity 24.9%); weakest is capital return (53rd, consecutive years of dividend increases 0 years, net share count bought back over the year 4.7). |
Health Care | 75.9 |
| 3 | Exelixis (EXEL) | Financial health 94th (debt to equity 0, free cash flow margin 37.7%).Financial health 94th (debt to equity 0, free cash flow margin 37.7%) and profitability 92nd (operating margin 37.6%, return on equity 36.2%); weakest is valuation (50th, price to book 7.8, price to earnings 18.2). |
Health Care | 73.0 |
| 4 | HARMONY BIOSCIENCES HLDG INC (HRMY) | Financial health 86th (free cash flow margin 40.1%, debt to equity 0.2).Financial health 86th (free cash flow margin 40.1%, debt to equity 0.2) and growth 84th (3-year revenue CAGR 25.6%, revenue growth year over year 24.3%); weakest is capital return (23rd, consecutive years of dividend increases 0 years, net share count bought back over the year -1.2). |
Health Care | 72.0 |
| 5 | Medpace (MEDP) | Financial health 90th (debt to equity 0, free cash flow margin 26.9%).Financial health 90th (debt to equity 0, free cash flow margin 26.9%) and profitability 87th (return on equity 98.3%, operating margin 21.1%); weakest is valuation (21st, price to book 38.5, price to earnings 35.1). |
Health Care | 70.5 |
| 6 | United Therapeutics (UTHR) | Financial health 93rd (debt to equity 0, free cash flow margin 32.7%).Financial health 93rd (debt to equity 0, free cash flow margin 32.7%) and profitability 85th (operating margin 46.9%, return on equity 18.8%); weakest is capital return (40th, consecutive years of dividend increases 0 years, net share count bought back over the year 1.2). |
Health Care | 68.4 |
| 7 | Regeneron Pharmaceuticals (REGN) | Capital return 93rd (net share count bought back over the year 5.7).Capital return 93rd (net share count bought back over the year 5.7) and financial health 85th (free cash flow margin 28.4%, debt to equity 0.1); weakest is growth (48th, 3-year revenue CAGR 5.6%, revenue growth year over year 9.3%). |
Health Care | 67.9 |
| 8 | KRYSTAL BIOTECH INC (KRYS) | Financial health 95th (free cash flow margin 48.5%, debt to equity 0).Financial health 95th (free cash flow margin 48.5%, debt to equity 0) and profitability 82nd (operating margin 41.5%, return on equity 16.8%); weakest is capital return (25th, consecutive years of dividend increases 0 years, net share count bought back over the year -0.7). |
Health Care | 67.9 |
| 9 | Halozyme (HALO) | Profitability 96th (return on equity 649.2%, operating margin 33.6%).Profitability 96th (return on equity 649.2%, operating margin 33.6%) and growth 91st (revenue growth year over year 41.2%, 3-year revenue CAGR 28.4%); weakest is valuation (24th, price to book 84.6, price to earnings 32). |
Health Care | 66.9 |
| 12 | Lilly (Eli) (LLY) | Profitability 97th (return on equity 77.8%).Profitability 97th (return on equity 77.8%) and growth 94th (revenue growth year over year 49.6%, 3-year revenue CAGR 31.7%); weakest is valuation (18th, price to book 31.9, price to earnings 38.6). |
Health Care | 66.1 |
Entered on 1 Oct 2026
United Therapeutics (UTHR) — Entered 1 Oct 2026: score 68.4, rank 6 (not compared with 1 Sep 2026 — those rows were scored under method version 3, this pass under 4, and the formula changed between them, so a score is only comparable within one version).
Regeneron Pharmaceuticals (REGN) — Entered 1 Oct 2026: score 67.9, rank 7 (not compared with 1 Sep 2026 — those rows were scored under method version 3, this pass under 4, and the formula changed between them, so a score is only comparable within one version).
Halozyme (HALO) — Entered 1 Oct 2026: score 66.9, rank 9 (not compared with 1 Sep 2026 — those rows were scored under method version 3, this pass under 4, and the formula changed between them, so a score is only comparable within one version).
Left on 1 Oct 2026
Amgen (AMGN) — Left 1 Oct 2026: score 64.0, rank 16 (not compared with 1 Sep 2026 — those rows were scored under method version 3, this pass under 4, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
CAREDX INC (CDNA) — Left 1 Oct 2026: score 53.1, rank 68 (not compared with 1 Sep 2026 — those rows were scored under method version 3, this pass under 4, and the formula changed between them, so a score is only comparable within one version) (a member leaves above rank 15).
See every rebalance of this list →
Informational only — NOT financial advice.